Search in:

Current Medical Research and Opinion Volume 37, 2021 - Issue 3

Submit an article Journal homepage

Open access

3,747

Views

CrossRef citations to date

Altmetric

Neurology

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

Patrick Vermerscha Inserm U1172, CHU Lille, FHU Imminent, University of Lille, Lille, France

Andrew Galazkab Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

Fernando Dangondc EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany

Doris Damianc EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany

Schiffon L. Wongc EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany

Dominic Jackd Merck KGaA, Darmstadt, Germany

Gerard Hartyd Merck KGaA, Darmstadt, GermanyCorrespondence[email protected]

show all

Pages 459-464 | Received 12 Nov 2020, Accepted 15 Dec 2020, Published online: 01 Feb 2021

Cite this article
https://doi.org/10.1080/03007995.2020.1865888
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (8)

Rosa Cortese, Giovanna Testa, Francesco Assogna & Nicola De Stefano. (2024) Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis. CNS Drugs 38:4, pages 267-279.
Crossref

Marien Gonzalez-Lorenzo, Ben Ridley, Silvia Minozzi, Cinzia Del Giovane, Guy Peryer, Thomas Piggott, Matteo Foschi, Graziella Filippini, Irene Tramacere, Elisa Baldin & Francesco Nonino. (2024) Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2024:1.
Crossref

Celia Oreja-Guevara, Wallace Brownlee, Elisabeth G. Celius, Diego Centonze, Gavin Giovannoni, Suzanne Hodgkinson, Christoph Kleinschnitz, Eva Kubala Havrdova, Melinda Magyari, Daniel Selchen, Patrick Vermersch, Heinz Wiendl, Bart Van Wijmeersch, Hashem Salloukh & Bassem Yamout. (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. Multiple Sclerosis and Related Disorders 69, pages 104459.
Crossref

David Magalashvili, Mathilda Mandel, Sapir Dreyer-Alster, Maria Didikin, Gil Harari, Shlomo Flechter & Anat Achiron. (2022) Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4. Journal of Neuroimmunology 372, pages 577966.
Crossref

Maria Petracca, Serena Ruggieri, Elena Barbuti, Antonio Ianniello, Roberta Fantozzi, Giorgia Teresa Maniscalco, Vincenzo Andreone, Doriana Landi, Girolama Alessandra Marfia, Maria Di Gregorio, Rosa Iodice, Leonardo Sinisi, Elisabetta Maida, Rosanna Missione, Cinzia Coppola, Simona Bonavita, Giovanna Borriello, Diego Centonze, Giacomo Lus, Carlo Pozzilli & Elisabetta Signoriello. (2022) Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurology and Therapy 11:3, pages 1193-1208.
Crossref

Gavin Giovannoni & Joela Mathews. (2022) Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review. Neurology and Therapy 11:2, pages 571-595.
Crossref

Giulio Disanto, Marcello Moccia, Rosaria Sacco, Antonio Luca Spiezia, Antonio Carotenuto, Vincenzo Brescia Morra, Claudio Gobbi & Chiara Zecca. (2022) Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Multiple Sclerosis and Related Disorders 58, pages 103490.
Crossref

Georgios Tsivgoulis, Spyros Deftereos, Claudio Gobbi, Elisabeth Gulowsen Celius, Alina Kulakowska, Giorgia Maniscalco, Irene Mendes & Nicolaos Grigoriadis. (2022) Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS). Journal of Central Nervous System Disease 14, pages 117957352110694.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

Articles from other publishers (8)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

Citations (8)

Articles from other publishers (8)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date